摘要
对于心室收缩不同步的心力衰竭患者,心脏再同步化治疗可缓解症状、降低死亡率。经典的心脏再同步化治疗主要用于纽约心脏病协会(NYHA)心功能Ⅲ-Ⅳ级患者。新近提出的心力衰竭4期分期提示,对心力衰竭患者应早期预防、早期治疗。最新研究提示,对NYHA心功能Ⅰ-Ⅱ级患者,心脏再同步化治疗可延迟心力衰竭的进展。
For heart failure patients with ventricular dyssynchrony, cardiac resynchronization therapy may improve symptoms and decrease mortality. Classic cardiac resynchronization therapy was mainly used for New York Heart Association （NYHA） 111-1V heart failure patients. Newly developed heart failure 4- stage classification suggests early prevention, early treatment for heart failure patients. Recently, many trials suggested cardiac resynchronization therapy were benefit for NYHA I - I1 heart failure patients.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2013年第5期358-361,共4页
Chinese Journal of New Drugs and Clinical Remedies
关键词
心脏再同步化治疗
心力衰竭
心室重构
除颤器
植入型
cardiac resynchronization therapy
heart failure
ventricular remodeling
defibrillators,implantable
